Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the asia-pacific region
MetadataShow full item record
BACKGROUND AND PURPOSE: Smoking and increased levels of blood pressure (BP) substantially increase the risk of cardiovascular diseases (CVD). If these 2 risk factors have a synergistic impact on cardiovascular events, lowering BP and quitting smoking will contribute more to reducing CVD than would be expected from ignoring their interaction. METHODS: Individual participant data were combined from 41 cohorts, involving 563 144 participants (82% Asian). During a median of 6.8 years follow-up, 4344 coronary heart disease (CHD) and 5906 stroke events were recorded. Repeat measures of systolic blood pressure (SBP) were used to adjust for regression dilution bias. Hazard ratios (HRs) and 95% confidence intervals (CIs) for SBP by cigarette smoking status were estimated from Cox proportional hazard models adjusted for age and stratified by study and sex. RESULTS: Data suggested a log-linear relationship between SBP and all subtypes of CVD. The HRs relating SBP to both CHD and ischemic stroke were broadly similar irrespective of smoking status (Pg‰¥0.1). For hemorrhagic stroke (intracerebral hemorrhage), the HRs (95% CIs) for an additional 10 mm Hg increment in SBP were 1.81 (1.73 to 1.90) for present smokers and 1.66 (1.59 to 1.73) for nonsmokers (P=0.003). For every subtype of cardiovascular events, similar results were found for analyses involving only fatal events. CONCLUSIONS: Smoking exacerbated the impact of SBP on the risk of hemorrhagic stroke. Although quitting smoking and lowering BP are both crucial for prevention of CVD, combining the 2 could be expected to have extra beneficial effect on preventing hemorrhagic stroke. © 2008 American Heart Association, Inc.
Showing items related by title, author, creator and subject.
Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease?: Meta-analysis of 419 488 individuals from the Asia pacific cohort studies collaborationTsukinoki, R.; Murakami, Y.; Huxley, Rachel; Ohkubo, T.; Fang, X.; Suh, I.; Ueshima, H.; Lam, T.; Woodward, M. (2012)Background and Purpose-: Elevated blood pressure and excess body mass index (BMI) are established risk factors for cardiovascular disease (CVD) but controversy exists as to whether, and how, they interact. Methods-: The ...
McNeil, J.; Wolfe, R.; Woods, R.; Tonkin, A.; Donnan, G.; Nelson, M.; Reid, Christopher; Lockery, J.; Kirpach, B.; Storey, E.; Shah, R.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Johnston, C.; Ryan, J.; Radziszewska, B.; Jelinek, M.; Malik, M.; Eaton, C.; Brauer, D.; Cloud, G.; Wood, E.; Mahady, S.; Satterfield, S.; Grimm, R.; Murray, A. (2018)Background: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who ...
Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly populationLewis, J.P.; Riaz, M.; Xie, S.; Polekhina, G.; Wolfe, R.; Nelson, M.; Tonkin, A.M.; Reid, Christopher ; Murray, A.M.; McNeil, J.J.; Shuldiner, A.R.; Lacaze, P. (2020)This article is protected by copyright. All rights reserved. The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response ...